Title |
Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved
|
---|---|
Published in |
BMC Research Notes, January 2016
|
DOI | 10.1186/s13104-016-1854-4 |
Pubmed ID | |
Authors |
Chiaki Saita, Risa Goto, Tomoyuki Aruga, Nami Idera, Yayoi Honda, Kazumi Horiguchi, Hiromi Miyamoto, Shinichiro Horiguchi, Toshinari Yamashita, Katsumasa Kuroi |
Abstract |
Invasive papillary carcinoma is a rare type of invasive ductal carcinoma. Neoadjuvant endocrine therapy is now considered as an optional therapy for postmenopausal women with hormone receptor-positive breast cancers, including invasive papillary carcinoma. We discuss the case of an 83-year-old postmenopausal Japanese female with hormone receptor-positive invasive papillary carcinoma who started treatment with an aromatase inhibitor and achieved pathological complete response after 12 months of endocrine treatment. Appropriate drugs and durations of neoadjuvant endocrine treatment have yet to be established. Continuing therapy with an aromatase inhibitor until the best clinical response is achieved may represent one of the best strategies in neoadjuvant endocrine therapy. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 10 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 3 | 30% |
Student > Bachelor | 2 | 20% |
Student > Doctoral Student | 2 | 20% |
Unknown | 3 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 4 | 40% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 10% |
Agricultural and Biological Sciences | 1 | 10% |
Nursing and Health Professions | 1 | 10% |
Unknown | 3 | 30% |